In recent years, the way many patients manage their diabetes has undergone a fundamental shift, with the role of wearables like continuous glucose monitors (CGMs) experiencing a notable uptick as patients move away from traditional finger prick methods for measuring blood glucose levels.
There has also been early signs of a shift towards measuring other markers such as ketones alongside glucose through continuous monitoring systems, with Abbott securing a CE mark and an approval from the US Food and Drug Administration (FDA) for its Libre Duo 10 day dual glucose-ketone monitor back in May and August 2026, respectively. This device was the first glucose-ketone monitor to reach the diabetes market.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In this episode of the GlobalData Healthcare podcast, Medical Device Network reporter, Annabel Kartal-Allen speaks with the co-founder, president and chief technology officer of BioLinq, Jared Tangney, about the current and future potential of continuous monitoring devices in the management of diabetes, as well as their role in other metabolic indications such as obesity.
On top of this, Jared homes in on the up-and-coming potential of continuously measuring other biomarkers alongside glucose, such as cortisol, lactate and ketones – which he says could help to paint a full picture of metabolic health, while allowing for the effective management of diseases under this umbrella.
If you enjoyed this episode of the GlobalData Healthcare podcast, you can find others focused on the world of medical devices, biotech, pharma and clinical trials at this link.
